Qube Research & Technologies (QRT)
LCTX icon

Qube Research & Technologies (QRT)’s Lineage Cell Therapeutics LCTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-259,561
Closed -$410K – 3813
2026
Q1 		$410K Buy
259,561
+48,213
+23% +$81.3K ﹤0.01% 2789
2025
Q4 		$353K Buy
+211,348
New +$366K ﹤0.01% 2904
2025
Q3 		– Sell
-39,036
Closed -$35.4K – 3801
2025
Q2 		$35.4K Buy
+39,036
New +$23.2K ﹤0.01% 3199
2024
Q3 		– Sell
-68,286
Closed -$68.1K – 3758
2024
Q2 		$68.1K Buy
68,286
+55,163
+420% +$60.9K ﹤0.01% 2676
2024
Q1 		$19.4K Buy
+13,123
New +$14.9K ﹤0.01% 3698
2023
Q2 		– Sell
-221,946
Closed -$333K – 2725
2023
Q1 		$333K Buy
221,946
+84,378
+61% +$118K ﹤0.01% 1711
2022
Q4 		$161K Buy
137,568
+34,246
+33% +$43.2K ﹤0.01% 1880
2022
Q3 		$117K Buy
103,322
+13,362
+15% +$19.6K ﹤0.01% 1924
2022
Q2 		$142K Buy
+89,960
New +$119K ﹤0.01% 1820
2021
Q2 		– Sell
-191,483
Closed -$450K – 2560
2021
Q1 		$450K Buy
191,483
+3,519
+2% +$8.45K 0.01% 1236
2020
Q4 		$331K Buy
187,964
+91,260
+94% +$128K ﹤0.01% 1307
2020
Q3 		$91K Sell
96,704
-38,434
-28% -$33.9K ﹤0.01% 1503
2020
Q2 		$118K Buy
+135,138
New +$119K ﹤0.01% 1493

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Qube Research & Technologies (QRT)'s LCTX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 259,561 shares — an estimated $410K sold.

Qube Research & Technologies (QRT) first reported a position in LCTX in Q2 2020 and held it in 13 quarters. The position peaked at $450K in Q1 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 259,561 Lineage Cell Therapeutics shares in Q2 2026, an estimated $410K.
  • Qube Research & Technologies (QRT) first reported a position in Lineage Cell Therapeutics in Q2 2020 and held it in 13 quarters.
  • Qube Research & Technologies (QRT)'s Lineage Cell Therapeutics position peaked at $450K in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.